Allergic Rhino-Conjunctivitis - Therapeutics Assessment Pipeline Review, H1 2014 adds “Allergic Rhino-Conjunctivitis – Pipeline Review, H1 2014” to its store. The report provides an overview of the Allergic Rhino-Conjunctivitis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Allergic Rhino-Conjunctivitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Rhino-Conjunctivitis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Complete report available @ .


  • The report provides a snapshot of the global therapeutic landscape of Allergic Rhino-Conjunctivitis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Allergic Rhino-Conjunctivitis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Allergic Rhino-Conjunctivitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Allergic Rhino-Conjunctivitis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Allergic Rhino-Conjunctivitis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Allergic Rhino-Conjunctivitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Allergic Rhino-Conjunctivitis Overview 8
Therapeutics Development 9
Pipeline Products for Allergic Rhino-Conjunctivitis - Overview 9
Pipeline Products for Allergic Rhino-Conjunctivitis - Comparative Analysis 10
Allergic Rhino-Conjunctivitis - Therapeutics under Development by Companies 11
Allergic Rhino-Conjunctivitis - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Allergic Rhino-Conjunctivitis - Products under Development by Companies 16
Allergic Rhino-Conjunctivitis - Companies Involved in Therapeutics Development 17
BioTech Tools 17
ALK-Abello A/S 18
FAES Farma SA 19
Allergy Therapeutics plc 20
Allergopharma Joachim Ganzer KG 21
Greer Laboratories, Inc. 22
Circassia Holdings Ltd. 23
Oxagen Limited 24
Laboratorios LETI S.L. 25
Immunomic Therapeutics, Inc. 26
Bial - Portela & Ca, S.A. 27
Allergic Rhino-Conjunctivitis - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
Pollinex Quattro Grass - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
short ragweed pollen allergen OD - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
MK-8237 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Grass Pollen Allergoid - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Olea Europaea Pollen Extract - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
AL-0704rP - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Acaroid - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Depigoid Birch - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
rPhleum - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Recombinant Birch Pollen Allergen - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Ragweed Pollen Extract - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Avanz Phleum Pratense - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
bilastine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
House Dust Mite-SPIRE - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Grass-SPIRE - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
gpASIT + TM - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ALK Birch Pollen Vaccine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Phleum Pratense - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Avanz Cupressus Immunotherapy for Allergic Rhino-Conjunctivitis - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Avanz Salsola Immunotherapy for Allergic Rhino-Conjunctivitis - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
JRC-LAMP-Vax - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
OC-2417 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Allergic Rhino-Conjunctivitis - Recent Pipeline Updates 66
Allergic Rhino-Conjunctivitis - Dormant Projects 76
Allergic Rhino-Conjunctivitis - Discontinued Products 77
Allergic Rhino-Conjunctivitis - Product Development Milestones 78
Featured News & Press Releases 78
Jun 09, 2014: ALK presents Phase III data on house dust mite SLIT-tablet at EAACI Annual Congress in Copenhagen 78
Mar 10, 2014: GREER Investigational Sublingual Allergy Immunotherapy Liquid (SAIL) for Short Ragweed Allergies Phase III Data Published in Journal of Allergy and Clinical Immunology 79
Jan 24, 2014: ALK announces posting of briefing documents for FDA Advisory Committee meeting on the ragweed sublingual tablet 80
Dec 12, 2013: Merck Statement on FDA Advisory Committee for GRASTEK, Merck's Investigational Sublingual Allergy Immunotherapy Tablet 81
Nov 09, 2013: Merck's Investigational Grass Sublingual Allergy Immunotherapy Tablet Significantly Reduced Allergy Symptoms and Need for Symptom-Relief Medication in Adults and Children in Pivotal Phase III Study 81
Apr 09, 2013: Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics 83
Mar 27, 2013: Merck Announces FDA Acceptance Of Biologics License Application For Investigational Grass Pollen Allergy Immunotherapy Tablet 84
Oct 23, 2012: ALK Announces North American Phase III Trial With Grass Allergy Immunotherapy Tablet Meets Primary Endpoint 84
Oct 04, 2012: Circassia Initiates Pivotal Phase III ToleroMune Trial In Cat Allergen-induced Rhinoconjunctivitis 85
Nov 28, 2011: Allergy Therapeutics Submits Complete Response To PEI In Germany And Clinical Study Protocol To FDA 86
Appendix 87
Methodology 87
Coverage 87
Secondary Research 87
Primary Research 87
Expert Panel Validation 87
Contact Us 88
Disclaimer 88

Browse more reports on Infectious Diseases Therapeutics Market @ .

About Us: is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.